DNA-PK inhibitors

A compound of formula I wherein: R1, R2 = H, an optionally substituted alkyl, heterocyclic or aryl group, or together with the N an optionally substituted heterocyclic group, preferably a morpholino group; and one of R3, R4 or R5 = an optionally substituted phenyl and the others are H. Most preferab...

Full description

Saved in:
Bibliographic Details
Main Authors NIALL MORRISON BARR MARTIN, DAVID RICHARD NEWELL, LAURENT JEAN MARTIN RIGOREAU, BERNARD THOMAS GOLDING, HILARY ALAN CALVERT, BERNARD PAUL NUTLEY, GRAEME CAMERON MURRAY SMITH, XIAO-LING FAN COCKCROFT, NICOLA JANE CURTIN, ROGER JOHN GRIFFIN, VINCENT JUNIOR MING-LAI LOH, PAUL WORKMAN, IAN ROBERT HARDCASTLE, FLORENCE RAYNAUD
Format Patent
LanguageEnglish
Published 06.07.2005
Edition7
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A compound of formula I wherein: R1, R2 = H, an optionally substituted alkyl, heterocyclic or aryl group, or together with the N an optionally substituted heterocyclic group, preferably a morpholino group; and one of R3, R4 or R5 = an optionally substituted phenyl and the others are H. Most preferably the compound has formula II. The compound is used as an adjunct in cancer therapy and in the treatment of retroviral diseases.
Bibliography:Application Number: GB20040024068